Compare Amylx Pharmaceuticals Inc (AMLX) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Kohl's Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $23.84 (market cap $2.64B), while Kohl's Corporation trades at $18.99 (market cap $2.10B). The key difference: Amylx Pharmaceuticals Inc is the larger of the two by market cap, and Kohl's Corporation pays a 2.7% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | KSS | |
|---|---|---|
Market Cap | $2.64B | $2.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $24.71 |
52-Week Low | $7.82 | $11.72 |
Enterprise Value | $2.39B | $8.20B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Kohl's (KSS) trades at $18.96, down 0.42% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock shows low valuation multiples (P/E of 7.77, P/S of 0.14) amid declining revenue, which fell to $16.22B in 2025. Recent Q1 2026 earnings beat expectations, and the company announced a $0.13 dividend for June 2026, alongside leadership changes including a new COO appointment in September 2026.
The outlook is mixed: low valuations and earnings beats offer value, but persistent sales declines and thin net margins near 1.77% pose risks. Analyst consensus is cautious with a $16.75 price target below the current price, reflecting concerns over competitive pressures and cash flow volatility. Investors should weigh cost-cutting progress against macroeconomic headwinds in retail.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
